Table 3 Designed clinical trials of agents targeting the Hippo pathway
From: Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
Agents | Mode of action | Study phase | Outcome | Study Title | NCT number |
|---|---|---|---|---|---|
Zoledronate, Atorvastatin | Inhibition of YAP/TAZ | Phase 2 | No results available | Neoadjuvant Zoledronate and Atorvastatin in TNBC | NCT03358017 |
Atorvastatin | Inhibits TAZ | Phase 2 | No results available | Targeting the Hippo transducer TAZ in breast cancer with Statins | NCT 02416427 |
Zoledronate | Inhibits YAP/TAZ | Phase 2 | No results available | Pre-operative zoledronate in TNBC | NCT 02347163 |